Abstract |
We present here the case-report of a man with a severe G6PD deficiency revealed after the use of rasburicase (uricolytic drug) during a chemotherapy protocol. The genotypic analysis done to confirm the biochemical measurement revealed the 'Mediterranean mutation' at the hemizygous state (G6PD gene is located on chromosome X). Consequently to this diagnose, a search for G6PD deficiency has been performed (at the biochemical and genotypic levels) for the 9 children (7 daughters and 2 sons) of the proband. Surprisingly, one of his son was found to be hemizygous for the mediterranean mutation and one of his daughter appeared homozygous for this same mutation. This implies that the proband's wife (not studied) is certainly heterozygous for the mediterranean mutation, as it is very unlikely that this mutation had appeared de novo for two children of this couple.
|
Authors | P Joly, C Bon, A Francina, M-C Gelineau, P Lacan, H Orfeuvre |
Journal | Annales de biologie clinique
(Ann Biol Clin (Paris))
2009 Jul-Aug
Vol. 67
Issue 4
Pg. 432-6
ISSN: 0003-3898 [Print] France |
Vernacular Title | Un déficit sévère en G6PD découvert au décours d'une chimiothérapie avec utilisation de rasburicase. |
PMID | 19654083
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Codon
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisolone
- Glucosephosphate Dehydrogenase
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Chromosomes, Human, Pair 10
- Codon
(genetics)
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Glucosephosphate Dehydrogenase
(blood, genetics)
- Glucosephosphate Dehydrogenase Deficiency
(diagnosis)
- Heterozygote
- Homozygote
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy)
- Male
- Middle Aged
- Mutation
- Pedigree
- Prednisolone
(administration & dosage)
- Vincristine
(administration & dosage)
|